Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Penumbra (PEN)

Penumbra Q4 revenue rises 28.7% to $284.7 million; sees 2024 revenue growth of 16%-20%

Positive Impact 3 of 5 earnings Written later

Penumbra reported fourth-quarter 2023 revenue of $284.7 million, up 28.7%, and GAAP net income of $54.2 million, or $1.38 per diluted share, which includes a $25.5 million tax benefit from a valuation allowance release. For 2024, the company projects total revenue of $1,230.0 million to $1,270.0 million, or 16% to 20% growth, and expects U.S. thrombectomy revenue to grow 27% to 30%.

Key points

  • Q4 2023 revenue was $284.7 million, up 28.7%; thrombectomy revenue was $190.8 million, up 42.4%
  • Q4 2023 GAAP net income was $54.2 million, or $1.38 per diluted share, including a $25.5 million tax benefit
  • Full-year 2023 revenue was $1,058.5 million, up 25.0%, and GAAP income from operations was $73.6 million versus $6.1 million in 2022
  • 2024 revenue is projected at $1,230.0 million to $1,270.0 million, or 16% to 20% growth over 2023

The filing

CompanyPenumbra (PEN)
Form8-K, current report
Filed with the SECFeb 22, 2024, 4:14 PM ET
Accession number0001321732-24-000023

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 22, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.